Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru

AIDS Research and Human Retroviruses

Volumn 30, Issue 5, 2014, Pages 416-424

  Tang, Eric C ^a   Sobieszczyk, Magdalena E ^a   Shu, Eileen ^a   Gonzales, Pedro ^b   Sanchez, Jorge ^b   Lama, Javier R ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AWARENESS; FEMALE; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEN WHO HAVE SEX WITH MEN; ORAL PREEXPOSURE PROPHYLAXIS; PERU; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROPHYLAXIS; REVIEW; TRANSGENDERISM; ANIMAL; DISEASE TRANSMISSION; HIV INFECTIONS; MALE HOMOSEXUALITY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; TRANSGENDER; UTILIZATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTI-HIV AGENTS; ATTITUDE OF HEALTH PERSONNEL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEALTH PERSONNEL; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PERU; PRE-EXPOSURE PROPHYLAXIS; TRANSGENDER PERSONS; YOUNG ADULT;

EID: 84899849694     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0212     Document Type: Review

References (42)

1. Scherrer AU, Ledergerber B, von Wyl V, et al.: Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011;53:1143-1152
2. Masquelier B, Taieb A, Reigadas S, et al.: Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy. J Antimicrob Chemother 2011;66: 1582-1589
3. Chaiwarith R, Praparattanapan J, Nuntachit N, Kotarathitithum W, Sirisanthana T, and Supparatpinyo K: Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy. Curr HIV Res 2011;9: 82-87
4. Fox MP, Cutsem GV, Giddy J, et al.: Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 2012;60:428-437
5. Wang X, Yang L, Li H, et al.: Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011;9:103-111
6. Lima VD, Bangsberg DR, Harrigan PR, et al.: Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010;55:460-465
7. Gras L, Kesselring AM, Griffin JT, et al.: CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007;45:183-192
8. Florence E, Lundgren J, Dreezen C, et al.: Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003;4:255-262
9. Zhang S, van Sighem A, Gras L, et al.: Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antivir Ther 2010;15:555-562
10. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, and Sterling TR: An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis 2011; 53:952-960
11. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50:1387-1396
12. Division of AIDS (DAIDS), U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institute of Mental Health (NIMH), et al.: HPTN 067 The ADAPT study: A phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/ tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). South Africa, Thailand. Accessed at www.hptn.org/ web%20documents/HPTN067/ Protocol/067ProtocolV3-01 Dec2011.pdf on June 6, 2013
13. French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) and Molina M: On demand antiretroviral pre-exposure prophylaxis for HIV in men who have sex with men (IPERGAY). France. Accessed at http://clinicaltrials.gov/show/NCT01473472 on June 6, 2013
14. National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, and Gulick RM: HPTN 069 NEXT-PReP: Phase II randomized, doubleblind, study of safety and tolerability of maraviroc, maraviroc + entricitabine, maraviroc + tenofovir or tenofovir + emtricitabine for preexposure prophylaxis to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. United States and Puerto Rico. Accessed at www.hptn.org/research-studies/HPTN069.asp#StudySummary on June 6, 2013
15. Mutua G, Sanders E, Mugo P, et al.: Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One 2012;7:e33103
16. MRC Clinical Trials Unit, McCormack S, and Dunn D: PROUD Pre-exposure option for reducing HIV in the UK: and open-label randomisation to immediate or deferred daily Truvada for HIV negative gay men. United Kingdom. Accessed at www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/ PROUD%20protocol%20v1. 1%2010September2012 .pdf on June 6, 2013
17. iPrExOLE: iPrEx Open Label Extension. Brazil, Ecuador, Peru, South Africa, Thailand, and United States. Accessed at www.iprexole.com/1pages/ aboutus/aboutus-whatisiprex ole.php on March 21, 2013
18. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and San Francisco Department of Public Health (SFDPH): The DEMO project. United States. Accessed at www.sfdph.org/ dph/files/newsMediadocs/2012PR/DemoProjectFINAL.pdf on June 6, 2013
19. California Collaborative Treatment Group, Morris S, and Moore D: CCTG 595: Text messaging to improve adherence to PrEP in high-risk MSM. United States. Accessed at http:// clinicaltrials.gov/show/NCT01761643 on June 6, 2013
20. HIV Prevention Trials Network, Shoptaw S, Magnus M, et al.: HPTN 073 Black men who have sex with men (MSM) pre-exposure prophylaxis (PrEP). United States. Accessed at www.clinicaltrials.gov/show/NCT01808352 on June 6, 2013
21. Oswaldo Cruz Foundation and Grinsztejn B: Implementation of the pre-exposure prophylaxis (PrEP) to HIV: a demonstrative project (DemoPrEP). Brazil. Accessed at http:// clinicaltrials.gov/show/NCT01989611 on December 28, 2013
22. National Institute of Mental Health and Underhill K: PrEP for HIV prevention in MSM: Mixed-methods study of behavior & message framing. United States. Accessed at http://cira.yale .edu/projects/prep-hiv-prevention-msm- mixed-methods-studybehavior-message-framing on June 6, 2013
23. Fenway Community Health and Mayer K: Pre-exposure prophylaxis adherence intervention for MSM (PrEPare). United States. Accessed at www.clinicaltrials. gov/show/ NCT01632397 on June 6, 2013
24. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and Hosek SG: An open label demonstration project and phase II safety study of pre-exposure prophylaxis use among 15 to 17 year old young men who have sex with men (YMSM). United States. Accessed at www.clinicaltrials.gov/show/NCT01769456 on June 6, 2013
25. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and Hosek SG: An open label demonstration project and phase II safety study of pre-exposure prophylaxis. United States. Accessed at www.clinicaltrials.gov/show/NCT01772823 on June 6, 2013
26. Gomez GB, Borquez A, Caceres CF, et al.: The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Perú: A mathematical modeling study. PLoS Med 2012;9:e1001323
27. Krakower DS, Mimiaga MJ, Rosenberger JG, et al.: Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One 2012;7:e33119
28. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, and Plot PK: Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS One 2012;7:e28238
29. Galea JT, Kinsler JJ, Salazar X, et al.: Acceptability of preexposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS 2011;22:256-262
30. Peinado J, Lama JR, Galea JT, et al.: Acceptability of oral versus rectal HIV preexposure prophylaxis among men who have sex with men and transgender women in Perú. J Int Assoc Provid AIDS Care 2013;12(4):278-283
31. Krakower D and Mayer KH: Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS 2012;7:593-599
32. White JM, Mimiaga MJ, Krakower DS, and Mayer KH: Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Pat Care STDs 2012;26:395-405
33. Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR, and Plot P: Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): A multinational qualitative study. BMJ Open 2012;2: e001234
34. Mimiaga MJ, Case P, Johnson CV, Safren SA, and Mayer KH: Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. JAIDS 2009;50:77-83
35. Anderson PL, Glidden DV, Liu A, et al.: Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4:151
36. Senn H, Wilton J, Sharma M, Fowler S, and Tan D: Knowledge of and opinions on HIV pre-exposure prophylaxis among front-line service providers at Canadian AIDS Service Organizations. AIDS Res Hum Retroviruses 2013;29(9): 1183-1189
37. Kapur A, Tang E, Tieu HV, Koblin B, Ellman T, and Sobieszczyk M: Knowledge, attitudes and willingness of New York City providers to prescribe oral pre-exposure prophylaxis (PrEP) for HIV prevention. XIX International AIDS Conference, Washington, DC, 2012. Abstract WEPE273
38. Centers for Disease Control and Prevention (CDC): Interim guidance: preexposure prophylaxis of the prevention of HIV Infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60:65-68
39. U.S. Food and Drug Administration (USFDA): FDA approves first drug for reducing the risk of sexually acquired HIV infection. United States. Accessed at www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210 .htm on March 21, 2013
40. World Health Organization (WHO): Guidance of oral preexposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. Switzerland. Accessed at http:// apps.who.int/iris/bitstream/10665/ 75188/1/9789241503884- eng.pdf on March 21, 2013
41. McCormack S, Fidler S, and Fisher M: The British HIV Association/British Association for Sexual Health and HIV position statement on pre-exposure prophylaxis in the UK. Int J STD AIDS 2012;23:1-4
42. Southern African HIV Clinicians Society Consensus Committee: Guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. S Afri J HIV Med 2012;13:40-55.